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BRIEF REPoRT
Introduction: The presence of the transforming fusion gene echi-
noderm microtubule-associated protein–like 4 (EML4)–anaplastic 
lymphoma kinase (ALK) in non–small-cell lung cancer (NSCLC) is 
a predictive marker for the efficacy of anaplastic lymphoma kinase 
inhibitors. However, the currently available assays for the detection 
of the different variants of EML4-ALK have limitations.
Methods: We developed an assay system for the detection of EML4-
ALK variants 1, 2, 3a, 3b, 4, 5a, 5b, 6, or 7 transcripts in total RNA 
obtained from formalin-fixed, paraffin-embedded (FFPE) specimens 
of NSCLC tissue. The assay is based on region-specific polymerase 
chain reaction amplification of EML4-ALK complementary DNA 
followed by specific single-base primer extension and analysis of the 
extension products by matrix-assisted laser desorption/ionization–
time of flight mass spectrometry. The assay was validated by fluores-
cence in situ hybridization and the results confirmed by subcloning 
and sequencing of polymerase chain reaction products.
Results: Evaluation of the analytic sensitivity of the assay with serial dilu-
tions of plasmids containing EML4-ALK complementary DNA sequences 
revealed it to be capable of the reliable detection of one copy of each plas-
mid per reaction. The assay also detected EML4-ALK variants 1 or 3 in 
three FFPE samples of surgically resected NSCLC shown to be positive 
for anaplastic lymphoma kinase rearrangement by fluorescence in situ 
hybridization. Furthermore, the assay identified variant 1 of EML4-ALK 
in 3 of 20 FFPE biopsy samples from patients with advanced NSCLC. All 
positive samples were confirmed by subcloning and sequencing.
Conclusions: our novel assay is highly sensitive and effective for the 
detection of EML4-ALK in FFPE specimens.
Key Words: EML4-ALK, Non–small cell lung cancer, Paraffin-
embedded tissue, Mass spectrometry, Diagnosis.
(J Thorac Oncol. 2012;7: 913–918)
Echinoderm microtubule-associated protein–like 4 (EML4)–anaplastic lymphoma kinase (ALK) was 
recently identified as a transforming fusion protein in lung 
cancer.1 Both EML4 and ALK genes are located on the short 
arm of chromosome 2. Multiple variants of EML4-ALK have 
been identified, with all variants including the same cyto-
plasmic portion of ALK but different portions of EML4 
(with truncations at exons 2, 6, 13, 14, 15, 18, and 20).2–4 
The most common EML4-ALK variants are 1 and 3, which 
together account for ~60% of EML4-ALK–positive cases of 
non–small cell lung cancer (NSCLC).5 Crizotinib, an inhibi-
tor of the tyrosine kinase activity of ALK and MET (hepato-
cyte growth factor receptor), has been shown to be effective 
for the treatment of lung cancer patients harboring EML4-
ALK.6 Indeed, crizotinib was recently approved by the U.S. 
Food and Drug Administration for the treatment of advanced 
NSCLC in patients with an abnormal ALK gene.
The EML4-ALK translocation occurs in 5 to 10% of 
lung cancer patients.1,2,7–10 Several assays have been developed 
for the detection of this translocation in clinical samples.2,4,11 
However, all of these assays have limitations with regard to 
sensitivity or the reliance on specialized techniques, with the 




Plasmids based on pCR2.1 or pcDNA3.1(+) and contain-
ing EML4-ALK or ALK complementary DNA (cDNA) were 
constructed as positive controls by TA cloning (Invitrogen, 
Madison, WI) or In-Fusion PCR cloning (Clontech, Palo Alto, 
CA).12 Details of plasmid construction and corresponding pri-
mer sequences are provided in Supplemental Digital Content 1 
(http://links.lww.com/JTo/A219) and 2 (http://links.lww.com/ 
JTo/A220).
Clinical Samples
Formalin-fixed, paraffin-embedded (FFPE) sam-
ples were obtained from NSCLC patients who had under-
gone surgery or biopsy for the purpose of diagnosis at 
Kinki University Hospital. The study was approved by the 
Institutional Review Board with the conditions that samples 
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FIGURE 1. MassARRAY method 
for the detection of EML4-ALK. 
The region of EML4-ALK comple-
mentary DNA containing the 
fusion point is amplified by poly-
merase chain reaction (PCR), with 
the amplicons ranging in size 
from 70 to 130 bp. After dephos-
phorylation of the 5’ terminus of 
the PCR products with the use 
of shrimp alkaline phosphatase, 
a single-base primer extension 
reaction is performed. The primer 
extension products are then 
analyzed by matrix-assisted laser 
desorption ionization–time of 
flight mass spectrometry . The 
single-base extension reaction 
occurs only when an EML4-ALK 
fusion product is present in the 
sample.
FIGURE 2. Representative spectra for EML4-ALK variants. Plasmid DNA (1 ng per reaction) containing the indicated variants of 
EML4-ALK (A) or total complementary DNA (5 ng per reaction) prepared from H3122 or H2228 cell lines (which harbor EML4-
ALK variant 1 and variants 3a and 3b, respectively) (B) was subjected to the MassARRAY assay. Representative spectra for exten-
sion products between ~5100 and ~6800 Da are shown. The expected m/z values for each single-base extension product are as 
indicated in Figure 1. Three independent experiments were performed in triplicate with identical results.
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be processed anonymously and analyzed for gene expres-
sion and that the study be disclosed publicly, according to the 
Ethical Guidelines for Human Genome Research published 
by the Ministry of Education, Culture, Sports, Science, and 
Technology, the Ministry of Health, Labor, and Welfare, and 
the Ministry of Economy, Trade, and Industry of Japan. The 
study also conforms to the provisions of the Declaration of 
Helsinki.
Cell Lines
The human NSCLC cell lines H2228 and H3122 were 
kindly provided by Dr. P. A. Jänne (Department of Medical 
oncology, Dana-Farber Cancer Institute, Boston, MA). Short 
tandem repeat analysis was performed with genomic DNA 
isolated from H2228 and H3122 cells. The DNA profile of 
H2228 cells matched that in the American Type Culture 
Collection short tandem repeat database. The cells were main-
tained under a humidified atmosphere of 5% Co
2
 at 37°C in 
RPMI 1640 medium (Sigma, St. Louis, Mo) supplemented 
with 10% heat-inactivated fetal bovine serum (Equitech-Bio, 
Kerrville, TX).
Sample Processing
Total RNA was extracted from cell lines and FFPE sam-
ples with the use of an RNeasy Mini Kit (Qiagen, Valencia, 
CA) and an RNeasy FFPE Kit (Qiagen), respectively. The 
percentage of tumor cells in each FFPE specimen was evalu-
ated by hematoxylin-eosin staining and found to be >10%. 
The isolated RNA was subjected to reverse transcription (RT) 
with the use of a High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA), and the resulting 
cDNA was stored at –80°C until analysis.
Detection of EML4-ALK
We used the MassARRAY iPLEX platform (Sequenom, 
San Diego, CA) for detection of EML4-ALK. The MassARRAY 
system involves a three-step process consisting of polymerase 
chain reaction (PCR), single-base primer extension, and separa-
tion of the products on a matrix-loaded silicon chip by matrix-
assisted laser desorption ionization (MALDI)–time of flight 
(ToF) mass spectrometry (MS) (Fig. 1). PCR and the single-
base primer extension reactions were performed in a thermal 
cycler (ABI-9700 instrument, Applied Biosystems), and the 
extension products were analyzed using the MALDI–ToF MS 
FIGURE 3. Sensitivity of EML4-ALK detection in plasmid DNA. The indicated copy numbers of pcDNA3.1(+) containing variants 
1, 3a, or 3b of EML4-ALK were assayed in the presence of 1 ng of normal human genomic DNA (A) or 10 pg of pCR2.1-alk plas-
mid DNA (B). The copy number of plasmid DNA per reaction was calculated according to the formula: 6.022 3 1023 3 [mass 
of DNA (g)]/[plasmid size (bp) 3 660]. Three independent experiments were performed in triplicate with identical results. UEP, 
unextended primer.
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(Sequenom). Detailed procedures and corresponding primer 
sequences are provided in Supplemental Digital Content 1 
(http://links.lww.com/JTo/A219) and 3 (http://links.lww.com/
JTo/A221), respectively.
Sequencing Analysis
PCR products were subcloned into the ToPo TA 
pCR2.1 vector (Invitrogen) and sequenced with an auto-
mated sequencer (ABI Prism 3100 Genetic Analyzer, Applied 
Biosystems) with the use of M13 universal primers.
Fluorescence In Situ Hybridization Analysis
FFPE tissue sectioned at a thickness of 4 μm and placed 
on glass slides was subjected to fluorescence in situ hybrid-
ization (FISH) with a break-apart probe for the ALK gene 
(Vysis LSI ALK Dual Color, Break Apart Rearrangement 
Probe; Abbott Molecular, Des Plaines, IL). FISH positivity 
was defined as the presence of >15% split signals in tumor 
cells.
RESULTS
Detection of EML4-ALK Variants
We developed an assay system based on the MassARRAY 
platform for the detection of EML4-ALK variants in NSCLC 
tissue (Fig. 1). The MassARRAY assay detected plasmid DNA 
corresponding to nine different EML4-ALK variants and wild-
type ALK (Fig. 2A). Appropriate mass spectra for the single-
base extension products were thus obtained (Figs. 1 and 2A). 
We next attempted to detect EML4-ALK in the human NSCLC 
cell lines H3122 and H2228, which harbor EML4-ALK vari-
ants 1 and 3, respectively.7 The RT-PCR products of total RNA 
isolated from the cell lines were subjected to the MassARRAY 
assay. EML4-ALK variant 1 was detected in H3122 cells, 
whereas variants 3a and 3b were detected in H2228 cells (Fig. 
2B). Wild-type ALK was also detected in both cell lines.
Sensitivity of the Assay
The major variant forms of EML4-ALK are variants 1, 
3a, and 3b, which account for ~60% of all EML4-ALK fusions.7 
FIGURE 4. Detection of EML4-ALK in formalin-fixed, paraffin-embedded (FFPE) samples of surgically resected non–small cell 
lung cancer tissue. (A) Clinical specimens were subjected to fluorescence in situ hybridization analysis with differentially labeled 
probes for the 5 (green) or 3 (red) regions of the ALK locus. A pair of split signals (arrows) indicates the rearranged ALK locus. 
(B) polymerase chain reaction (PCR) products derived with PCR primer sets in the MassARRAY assay were separated with the 
use of an Agilent 2100 Bioanalyzer and a DNA 1000 LabChip Kit (Agilent Technologies, Inc., Palo Alto, CA). The PCR products 
are from pcDNA3.1(+)-v1 (lane 1), pcDNA3.1(+)-v3a (lane 2), pcDNA3.1(+)-v3b (lane 3), case 1 (lane 4), case 2 (lane 5), and 
case 3 (lanes 6 and 7). The asterisk indicates the corresponding band in each case. (C) Total RNA (10 ng) isolated from the FFPE 
samples in (A) was analyzed by the MassARRAY assay. Representative spectra are shown. The experiment was repeated twice 
with identical results. (D) The PCR products from (C) were also subcloned and sequenced. ex, exon.
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We therefore examined the sensitivity of our assay for detec-
tion of these variants. Samples containing 1000, 100, 10, or 1 
copy of plasmid DNA [pcDNA3.1(+) for variants 1, 3a, or 3b] 
and 1 ng of normal human genomic DNA (Promega, Madison, 
WI) were prepared by 10-fold serial dilution. MS spectra 
revealed a clear peak at the expected size for variants 1, 3a, or 
3b in all samples, including those containing only one copy of 
the variant DNA (Fig. 3A). We also examined assay sensitivity 
when the samples were diluted with pCR2.1 containing ALK 
cDNA (pCR2.1-alk). Samples containing 1000, 100, 10, or 1 
copy of the variant plasmids were thus diluted with 10 pg (~2 
× 106 copies) of pCR2.1-alk. A clear peak at the expected size 
was again detected in all the samples including those contain-
ing only one copy of the variant DNA (Fig. 3B). These results 
therefore suggested that the sensitivity of the assay for the 
detection of EML4-ALK variants is high.
Detection of EML4-ALK Variants in FFPE 
Samples
We next evaluated the ability of our assay to detect 
EML4-ALK variants in three surgically resected FFPE sam-
ples of NSCLC shown to be positive for ALK rearrangements 
by FISH analysis (Fig. 4A). The primary PCR products for 
the assay were also analyzed by gel electrophoresis, with the 
expected sizes of the amplification products being 115, 103, 
and 119 bp for variants 1, 3a, and 3b, respectively. Bands cor-
responding to EML4-ALK variant 1 (case 2), variant 3a (cases 
1 and 3), and variant 3b (case 3) were detected (Fig. 4B). 
Similarly, we detected MS peaks corresponding to EML4-
ALK variant 1 and to variants 3a or 3b in case 2 and in cases 
1 and 3, respectively (Fig. 4C). The presence of EML4-ALK 
variants in these three cases was confirmed by subcloning and 
sequencing of PCR products (Fig. 4D). We further analyzed 
several NSCLC specimens shown to be negative for EML4-
ALK by FISH analysis; no mass peaks for EML4-ALK variants 
were detected by the MassARRAY assay (data not shown). 
These results thus suggested that the MassARRAY assay is 
able to detect EML4-ALK variants in FFPE samples.
FIGURE 5. Detection of EML4-
ALK in formalin-fixed, paraffin-
embedded samples of non–small 
cell lung cancer obtained by 
transbronchial lung biopsy. 
(A) Representative spectra of 
EML4-ALK–positive samples. The 
experiments were repeated twice 
with identical results. (B) The 
polymerase chain reaction prod-
ucts from (A) were subcloned and 
sequenced.
TABLE 1. Characteristics of Patients Screened for EML4-ALK
No.
Age  
(years) Sex Histology Procedure
Smoking 
status EML4-ALK
1 63 F Ad TLB Never Negative
2 62 M Ad TBLB Current Negative
3 74 M Ad TLB Current Negative
4 71 M Ad TBLB Current Negative
5 63 F Ad TBLB Never Variant 1
6 75 M Ad TBLB Former Negative
7 59 M Ad Needle biopsy Current Negative
8 85 M Ad TBLB Current Negative
9 73 F Ad Lymph node biopsy Never Negative
10 68 F Ad TBLB Current Negative
11 65 M Ad TBLB Current Variant 1
12 57 M Ad TBLB Current Negative
13 68 F Ad TLB Never Negative
14 73 M Ad TBLB Former Negative
15 67 F Ad TBLB Never Negative
16 67 M Ad TBLB Former Negative
17 57 M Ad TBLB Former Negative
18 56 M Large TBLB Current Negative
19 65 M Ad TBLB Current Negative
20 60 M Ad TBLB Current Variant 1
Ad, adenocarcinoma; Large, large cell carcinoma; TLB, thoracoscopic lung biopsy; 
TBLB, transbronchial lung biopsy.
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Screening for EML4-ALK Variants in FFPE 
Biopsy Samples of Advanced NSCLC
Molecular analysis of biopsy samples from patients 
with advanced NSCLC is often difficult because of the 
small amount of tissue available. We therefore examined 
the feasibility of detection of EML4-ALK variants with the 
MassARRAY assay in FFPE biopsy specimens obtained 
from 20 patients with advanced NSCLC, the characteristics 
of whom are shown in Table 1. Three specimens (samples 5, 
11, and 20) were found to be positive for variant 1 of EML4-
ALK, with none of the other variants being detected (Fig. 5A). 
The presence of EML4-ALK variant 1 in these three cases was 
confirmed by subcloning and sequencing of PCR products 
(Fig. 5B). We also performed FISH analysis on the 20 FFPE 
specimens. of the three EML4-ALK–positive cases detected 
by the MassARRAY assay, two (samples 5 and 20) were posi-
tive by FISH whereas the third (sample 11) could not be evalu-
ated because of poor tissue quality (data not shown). None of 
the cases that tested negative by the MassARRAY assay was 
positive by FISH. These results thus suggested that our assay 
is effective for EML4-ALK screening with FFPE biopsy speci-
mens of advanced NSCLC.
DISCUSSION
We have developed a MassARRAY assay for screening 
of EML4-ALK in FFPE samples of NSCLC tissue. This novel 
assay is capable of detecting nine different EML4-ALK vari-
ants with a high sensitivity.
Dual-color split-signal FISH analysis has been consid-
ered the gold standard in screening for ALK rearrangement. 
However, given that EML4 and ALK loci are located in rela-
tively close proximity on chromosome 2p, the detection of the 
EML4-ALK fusion gene on the basis of the gap between the 
probes is sometimes difficult. The identification and counting 
of signals on tissue sections is impeded by factors such as cut-
ting artifacts and nuclear overlap related to the thickness and 
homogeneity of the tissue sections and the size of the nuclei. 
The MassARRAY system is a nucleic acid analysis platform 
which utilizes a three-step process composed of PCR ampli-
fication, single-base primer extension, and MALDI–ToF MS 
analysis. The presence of EML4-ALK in our MassARRAY 
assay is detected on the basis of the presence of products of 
predicted mass.
The amount of tumor tissue available for molecular 
analysis is often limited in patients with advanced NSCLC. 
Furthermore, RNA extracted from FFPE samples is highly 
degraded and less amenable to RT-PCR analysis compared 
with that isolated from nonfixed, freshly frozen tissue. We 
succeeded in amplifying EML4-ALK cDNA by PCR from 
FFPE tissue with primers designed to yield short amplicons 
(70–130 bp). The design of such short amplicons can also be 
applied to quantitative PCR systems such as amplification-
refractory mutation system for allele-specific PCR assays. 
In our system, PCR amplification was performed with a high 
number of cycles (45 cycles), and increased accumulation of 
PCR products conferred higher sensitivity. We tested 20 FFPE 
biopsy samples from patients with NSCLC with our assay and 
detected a clear mass peak for EML4-ALK variant 1 in 3 of 
these samples, each of which was confirmed positive for this 
variant by subcloning and sequencing of the PCR products. 
In contrast to FISH, our assay is able to distinguish between 
the different EML4-ALK variants in a small amount of FFPE 
NSCLC tissue, and it should prove to be a useful tool for the 
detection of EML4-ALK variants in diagnostic testing for this 
fusion gene.
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